The high-throughput, scalable BD Cor system for infectious disease diagnostics is now available in Europe with the firm's BD Onclarity HPV assay.
Last year, the firm saw 21 percent growth in reproductive health, 56 percent growth in oncology, and 49 percent growth in infectious disease testing.
The study showed that the Zeesan test kit and qPCR instrument could be used for near-patient HPV typing of 94 samples in 2.5 hours.
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
Most head and neck cancer patients saw a decline in oral HPV DNA after treatment, but those who did not were more likely to experience disease recurrence.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.
A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.
Broad Institute researchers describe an approach they've dubbed "DNA microscopy."
In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.